Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Next-Gen Immunomodulatory Nanoplatforms Targeting Regulatory T Cell Metabolism to combat cancer

Obiettivo

Regulatory T cells (Tregs) are vital for maintaining homeostasis and self-tolerance. This immunosuppressive nature is exploited by cancer for tumour growth. Consequently, Treg accumulation in tumors is associated with poor prognosis and is a fundamental impediment to the success of immunotherapy. Thus, Treg suppressive mechanisms emerge as appealing therapeutic targets. However, current approaches focus on their systemic elimination, failing to yield significant clinical outcomes and are accompanied by harmful autoimmune toxicities. The ERC-funded project RegSign discovered a novel, unexpected metabolic mechanism whose therapeutic targeting has the unique advantage of restraining the immunosuppressive action of Tregs specifically in the tumor, without eliminating them, while protecting their beneficial effect on the periphery. Based on these findings, this PoC project, MetaReg will develop and validate Treg-targeted nanoplatforms tailoring Treg metabolism to disrupt their immunosuppressive function specifically in tumors while preserving their fitness in the periphery. To navigate the pathway from research to innovation, MetaReg will optimize the nanosystems, demonstrate their safety and efficacy in humanized mouse models, secure IP, and assess licensing strategies. MetaReg envisions bridging the “valley of death” between fundamental discoveries and clinical translation, opening new avenues in cancer immunotherapy.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) ERC-2025-POC

Vedi tutti i progetti finanziati nell’ambito del bando

Istituzione ospitante

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON
Contributo netto dell'UE
€ 150 000,00
Indirizzo
SORANOU EFESIOU 4
115 27 ATHINA
Grecia
Regione
Αττική Aττική Κεντρικός Τομέας Αθηνών
Tipo di attività
Research Organisations
Collegamenti
Costo totale
Nessun dato

Beneficiari (1)